Edwards Lifesciences misses Q2 earnings expectations, cuts FY 2022 guidance

Trending News🌧️

Edwards Lifesciences ($NYSE:EW) reported second-quarter earnings that missed expectations and cut its full-year guidance, sending shares lower in after-hours trading. The heart-focused medical device maker posted non-GAAP earnings per share of $0.63, missing estimates by $0.01. The company attributed the miss and guidance cut to lower-than-expected sales in its transcatheter mitral valve repair (TMVR) business. Despite the miss, Edwards’ CEO Michael A. Mussallem said the company remains “confident in the long-term opportunity” for TMVR. Shares of Edwards Lifesciences lost 5.9% to $101 after hours.

Market Reaction

On Thursday, shares of Edwards Lifesciences Corporation opened at $105.8 and closed at $107.3, up 1.6% from the previous day’s close of $105.6. This came after the company missed earnings expectations for the second quarter of 2021 and cut its guidance for the full year. Overall, sentiment towards the company has been mixed since the news was published. Some investors are worried about the company’s ability to meet its full-year guidance, while others believe that the recent pullback in the stock price presents a buying opportunity.

VI Analysis

Edwards Lifesciences is a strong company in terms of its fundamentals, with a strong position in terms of assets, profitability and growth.

However, it is weak in terms of dividends. Edwards Lifesciences has a high health score of 8/10, indicating that it is capable of sustaining future operations in times of crisis. Edwards Lifesciences is classified as a ‘gorilla’ company, meaning that it has achieved stable and high revenue or earning growth due to its strong competitive advantage. At the right price, it is suitable for investors seeking high capital gains.

However, high growth companies are generally considered to be more risky as they attempt to grow faster.

For more details please visit Star Chart.

Summary

Edwards Lifesciences ($NYSE:EW) missed earnings expectations for the second quarter of 2021 and cut its full-year guidance for 2022. The mixed news sent the stock price up 1.6% the following day. The company attributed the earnings miss to lower-than-expected sales of its transcatheter aortic valve replacement (TAVR) products.